Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline...
Tyra Biosciences Inc reported a Q4 net loss of $22.8M, up from $12.9M last year, with R&D expenses doubling to $20.7M. The company's cash position is strong at $403.5M, supporting operations through 2026. Progress includes advancing TYRA-300 for mUC treatment and SURF301 Phase 1 study, with key milestones expected in 2024.
Reference News
Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline...
Tyra Biosciences Inc reported a Q4 net loss of $22.8M, up from $12.9M last year, with R&D expenses doubling to $20.7M. The company's cash position is strong at $403.5M, supporting operations through 2026. Progress includes advancing TYRA-300 for mUC treatment and SURF301 Phase 1 study, with key milestones expected in 2024.